{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-006194","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2023-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.594524+00:00","generated_at":"2026-06-20T10:38:38.315044+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Precigen reports positive Phase 1 PRGN-2012 data: 50% complete response in RRP patients","bullets":["50% of RRP patients at Dose Level 2 achieved Complete Response, requiring no post-treatment surgeries.","Median annual RRP surgeries dropped from 6.5 pre-treatment to 0.5 post-treatment at Dose Level 2.","PRGN-2012 well-tolerated with no dose-limiting toxicities and no treatment-related Grade ≥3 adverse events.","Preliminary cash, equivalents, and investments totaled ~$56M as of Dec 31, 2022; restricted cash ~$43.7M.","Phase 2 study enrolling; 32 patients enrolled at Dose Level 2 to date; FDA discussions advancing for regulatory strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-006194","json":"https://secwatch.observer/filing/0001104659-23-006194.json","markdown":"https://secwatch.observer/filing/0001104659-23-006194.md","text":"https://secwatch.observer/filing/0001104659-23-006194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000110465923006194/0001104659-23-006194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000110465923006194/tm234280d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T10:38:38.315044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}